Community post

Adaptive Phage Therapeutics (APT), having recently doubled its biologics manufacturing capability (intended for its upcoming phage clinical trials), is currently in talks with a partner to help with rapid production of a COVID-19 vaccine candidate for a clinical study. APT does not anticipate delays with its phage trials, and plans to soon expand its workforce (doubling or tripling its 30-person size).